Theranica, a Netanya, Israel- and Montclair, NJ-based prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other idiopathic pain conditions, closed its Series C funding round, with a first closing of $45m.
The round was led by New Rhein Healthcare Investors, with participation from existing investors aMoon, Lightspeed Venture Partners, LionBird, Takoa Invest, and Corundum Open Innovation.
The company, which has extended the financing round, planning a final closing in October, intends to use the funds to expand its commercial activity in the U.S.
Led by Alon Ironi, CEO, and and Dr. Shimon Eckhouse, Chairman and Co-Founder, Theranica is a prescribed digital therapeutics company dedicated to creating effective, safe, affordable, low-side effect therapies for idiopathic pain conditions. It provides an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of episodic and chronic migraine in people aged 12 and older. Worn on the upper arm at the onset of a migraine attack, Nerivio alleviates migraine headache and associated symptoms by utilizing remote electrical neuromodulation to trigger an endogenous analgesic mechanism, known as conditioned pain modulation.
Eligible for insurance coverage and available to patients seeking cost-effective drug-free therapies for migraine, Nerivio can be prescribed by any certified healthcare provider in the U.S. and is shipped to patients’ homes through several specialty pharmacies.
FinSMEs
29/08/2022